In pancreatic cancer, the nanofluidic device avoids systemic treatment that leads to adverse side effects.

‘In animal models, the new nanofluidic device was found to decrease pancreatic tumor at a fourfold lower dosage than traditional systemic immunotherapy treatment.’

Pancreatic ductal adenocarcinoma is frequently diagnosed at advanced stages. In fact, about 85% of patients already have metastatic disease at diagnosis. 




The Houston Methodist researchers are studying similar nanofluidic delivery technology on the International Space Station. Grattoni’s nanomedicine lab at Houston Methodist focuses on implantable nanofluidics-based platforms for controlled and long-term drug delivery and cell transplantation to treat chronic diseases.
The Best Implantable Devices for Shrinking Pancreatic Tumors
Immunotherapy holds promise in treating cancers that previously did not have good treatment options. However, because immunotherapy is delivered throughout the entire body, it causes many side effects that are sometimes long-lasting, if not life-long. By focusing the delivery directly into the tumor, the body is protected from being exposed to toxic drugs and fewer side effects, essentially allowing patients undergoing treatment to have a better quality of life.“Our goal is to transform the way cancer is treated. We see this device as a viable approach to penetrating the pancreatic tumor in a minimally invasive and effective manner, allowing for a more focused therapy using less medication,” said Alessandro Grattoni, Ph.D., co-corresponding author and chair of the Department of Nanomedicine at Houston Methodist Research Institute.
The NDES device consists of a stainless-steel drug reservoir containing nanochannels, thus creating a membrane that allows for sustained diffusion when the drug is released.
Other medical technology companies offer intratumoral drug-eluting implants for cancer therapeutics, but those are intended for shorter duration use.
Advertisement
Source-Eurekalert